UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 29, 2007
COMBINATORX, INCORPORATED
(Exact name of Registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
000-51171 |
| 04-3514457 |
(Commission File No.) |
| (IRS Employer Identification No.) |
245 First Street
Sixteenth Floor
Cambridge, MA 02142
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (617) 301-7000
Not Applicable |
(Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01. Entry into a Material Definitive Agreement.
On March 29, 2007, CombinatoRx amended its secured equipment line of credit with General Electric Capital Corporation to increase the line of credit by $877,000, and CombinatoRx also borrowed an additional $1.1 million under the amended line of credit. Additional amounts borrowed under the amended facility are repayable over 48 months in the case of laboratory and scientific equipment, and 36 months in the case of other equipment, and amounts borrowed bear interest at the rate of 10.12% per annum.
Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.
See the description in Item 1.01 of CombinatoRx’s direct financial obligations under the amendment to the equipment line of credit.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits
Exhibit No. |
| Description |
|
10.1 |
| Promissory Note, dated as of March 29, 2007, between General Electric Capital Corporation and |
|
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| COMBINATORX, INCORPORATED | |
|
|
|
| By: | /s/ Robert Forrester |
| Name: | Robert Forrester |
| Title: | Executive Vice President and |
Dated: April 4, 2007
3
Index to Exhibits
Exhibit No. |
| Description |
|
10.1 |
| Promissory Note, dated as of March 29, 2007, between General Electric Capital Corporation and CombinatoRx, Incorporated. |
|
4